National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Cancer (1)
- Children/Adolescents (1)
- Comparative Effectiveness (2)
- (-) Digestive Disease and Health (5)
- Evidence-Based Practice (1)
- Healthcare Utilization (1)
- Medication (2)
- Neurological Disorders (1)
- Nutrition (1)
- Outcomes (2)
- Patient-Centered Outcomes Research (2)
- Racial and Ethnic Minorities (1)
- Surgery (1)
- (-) Treatments (5)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 5 of 5 Research Studies DisplayedNguyen NH, Luo J, Paul P
Effectiveness and safety of biologic therapy in Hispanic vs non-Hispanic patients with inflammatory bowel diseases: a CA-IBD cohort study.
Researchers compared risk of hospitalization, surgery, and serious infection in Hispanic versus non-Hispanic adult patients with inflammatory bowel diseases (IBDs) who were new recipients of biologic therapy. Their findings indicate that Hispanic patients experienced higher hospitalization, surgery, and serious infection rates. The researchers concluded that future studies should investigate the biological, social, and environmental drivers of these differences.
AHRQ-funded; HS019913.
Citation: Nguyen NH, Luo J, Paul P .
Effectiveness and safety of biologic therapy in Hispanic vs non-Hispanic patients with inflammatory bowel diseases: a CA-IBD cohort study.
Clin Gastroenterol Hepatol 2023 Jan;21(1):173-81.e5. doi: 10.1016/j.cgh.2022.05.008..
Keywords: Digestive Disease and Health, Racial and Ethnic Minorities, Treatments
Khorfan R, Schlick CJR, Yang AD
Utilization of minimally invasive surgery and its association with chemotherapy for locally advanced gastric cancer.
This study compared outcomes of patients with T3 or greater and/or N+ gastric carcinoma who had minimally invasive surgery (MIS) or traditional open surgery. Patients who received MIS had a greater likelihood of receiving postoperative chemotherapy. Patients from the National Cancer Database (21,872) from 2010 to 2015 were identified. The majority (72.2%) received open surgery although MIS rates went up during that time period. Predictors of MIS were Asian race, any insurance coverage and treatment at high-volume centers. Survival rates were higher for MIS patients although that could be explained by their increased likelihood of receiving adjuvant chemotherapy.
AHRQ-funded; HS026385.
Citation: Khorfan R, Schlick CJR, Yang AD .
Utilization of minimally invasive surgery and its association with chemotherapy for locally advanced gastric cancer.
J Gastrointest Surg 2020 Feb;24(2):243-52. doi: 10.1007/s11605-019-04410-x.
.
.
Keywords: Surgery, Treatments, Cancer, Digestive Disease and Health, Healthcare Utilization, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice
Stone B, Hester G, Jackson D
Effectiveness of fundoplication or gastrojejunal feeding in children with neurologic impairment.
Gastroesophageal reflux (GER), aspiration, and secondary complications lead to morbidity and mortality in children with neurologic impairment (NI), dysphagia, and gastrostomy feeding. Fundoplication and gastrojejunal (GJ) feeding can reduce risk. A comparison of GJ to fundoplication using first-year postprocedure reflux-related hospitalization (RRH) rates found that in children with NI, GER, and dysphagia,:fundoplication and GJ feeding have similar RRH outcomes.
AHRQ-funded; HS019862.
Citation: Stone B, Hester G, Jackson D .
Effectiveness of fundoplication or gastrojejunal feeding in children with neurologic impairment.
Hosp Pediatr 2017 Mar;7(3):140-48. doi: 10.1542/hpeds.2016-0126.
.
.
Keywords: Children/Adolescents, Digestive Disease and Health, Neurological Disorders, Nutrition, Outcomes, Treatments
McLean LP, Cross RK
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
This review discusses the chemistry, pharmacologic properties, clinical efficacy, and safety of vedolizumab in ulcerative colitis. It concluded that vedolizumab is a promising new agent for the treatment of ulcerative colitis. Its mechanism of action differs from tumor necrosis factor (TNF)-alpha inhibitors and immune suppressants, allowing it to be used in cases of TNF-alpha inhibitor failure or non-response, or as a first-line biologic drug.
AHRQ-funded; HS018975.
Citation: McLean LP, Cross RK .
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
Expert Opin Drug Metab Toxicol 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171.
.
.
Keywords: Comparative Effectiveness, Digestive Disease and Health, Medication, Treatments
Hazelwood GS, Rezaie A, Borman M
Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
The authors compared therapies for induction and maintenance of remission in patients with Crohn's disease. They found that adalimumab and infliximab + azathioprine are the most effective therapies for induction and maintenance of remission of Crohn's disease.
AHRQ-funded; HS021747.
Citation: Hazelwood GS, Rezaie A, Borman M .
Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Gastroenterology 2015 Feb;148(2):344-54.e5; quiz e14-5. doi: 10.1053/j.gastro.2014.10.011.
.
.
Keywords: Comparative Effectiveness, Digestive Disease and Health, Medication, Patient-Centered Outcomes Research, Treatments